REGN — Regeneron Pharmaceuticals, Inc.

Is REGN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of July 5, 2026

Regeneron Pharmaceuticals, Inc. (REGN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Biotechnology) last closed at $654.27. The rating moved from Neutral to Overbought on July 2, 2026 and has changed 34 times in the last 90 days.

Public ratingOverbought (as of July 5, 2026)
Last close$654.27
Rating changesRating changed 34 times in the last 90 days
Last changeMoved from Neutral to Overbought on July 2, 2026
SectorHealthcare
IndustryBiotechnology

Latest MarketMoodz coverage

FDA Selects Firms for PreCheck to Speed New Drug Plants2026-06-29
Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
Regeneron Strikes Deal With Trump Admin to Cut Drug Prices2026-04-24
Regeneron Price Concessions Under Trump Policy; Free Hearing-Loss Therapy2026-04-23
FDA Expands Dupixent Use as Sanofi Reports Earnings Beat2026-04-23

See today's live rating, score and targets

Members see the live hourly rating for REGN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.